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Abstract
In this article a generalized mathematical model describing the interactions between malignant
tumour and immune system with discrete time delay incorporated into the system is considered.
Time delay represents the time required to generate an immune response due to the immune
system activation by cancer cells. The basic mathematical properties of the considered model,
including the global existence, uniqueness, non-negativity of the solutions, the stability of steady
sates and the possibility of the existence of the stability switches, are investigated when time delay
is treated as a bifurcation parameter. The model is validated with the sets of the experimental data
and additional numerical simulations are performed to illustrate, extend, interpret and discuss the
analytical results in the context of the tumour progression.
Keywords: delay differential equations, stability analysis, Hopf bifurcation, immune system,
tumour, immunotherapy
Acknowledgements
This work was supported by the Polish Ministry of Science and Higher Education, within the Iuventus
Plus Grant: ”Mathematical modelling of neoplastic processes" grant No. IP2011 041971.
ar
X
iv
:1
50
5.
02
03
0v
2 
 [q
-b
io.
TO
]  
4 N
ov
 20
15
21 Introduction
Cancer immunology is a new trend in immunology that focuses on the variety of interactions between
the immune system and cancer cells. The aim of cancer immunology is to discover new cancer
immunotherapies to fully cure or at least to retard the progression of the disease. According to recent
reports [1] lymphocytes sensitive to tumour antigens are often present in the patient’s body, providing
a potentially natural way to prevent tumour growth. On the other hand, it is also observed that the full
immune response usually does not occur and so the natural protection afforded by the immune system
is ineffective.
In general the interactions between tumour cells and immune system are very complex and involve
a number of different kinds of molecules, immune cells and events, [2]. The immune response against
tumour antigens involves different kinds of immune cells: B-Lymphocytes producing and secreting
antibodies into the blood or placing them on their surfaces, cytotoxic T-Lymphocytes – the effec-
tor cells that destroy the antigens and thus the antigen-bearing cells, T helper-lymphocytes secreting
interleukins, hence stimulate both T and B cells to divide and finally T-suppressor cells that end the
immune response. All these cells are produced in the body from a small fraction of the precursor cells.
Whenever antigens are presented to the precursor cells they are activated, start to proliferate and then
differentiate into effector or memory cells. Unfortunately, these mechanism do not guarantee the fully
efficient response of the immune system due mainly to the tumour’s own defence system. Tumour
cells protect themselves from contact with lymphocytes by, amongst other methods, surface expres-
sion of ligands which initiate the apoptotic signal in the cytotoxic T-Lymphocytes, thus killing off the
cytotoxic T-Lymphocytes before the necessary cell-contact with the tumour cells can be initiated.
Clearly, due to the complexity of the considered problem systems describing most of the tumour-
immune system interactions would involve a large number of variables and thus equations, as in [3],
where a model of 12 equations is proposed and numerically analysed or in [4], where a system of 5
equations describing the response of the effector cells to the growth of tumour cells is studied. More
recently, systems of four or more equations investigating the immunotherapy and its improvement
for high grade gliomas ( [5, 6]), predicting outcomes of prostate cancer personalized immunother-
apy ( [7]) or humoral mediated immune response [8] were proposed. Also well known immune
system Marchuk’s model, [9–11], describing the immune system dynamics which was applied to
the description of the tumour growth phenomenon, see e.g. [12]. However, to better understand the
main underlying mechanism of immune response to the presence of the tumour cells complex models
were simplified and thus reduced into two- or three-equation and less detailed ones, see e.g. [13–19]
or [20–26].
In this article the influence of a particular modification to the generalization of the two-equation
model proposed in [19] is studied. The proposed generalization concerns the form of the stimulus
function, namely only some essential assumptions regarding the shape and regularity of this function
are assumed for the theoretical part of the paper. The proposed modification reflects the fact that the
immune system requires some time before the presence of a tumour (actually, tumour antigens) in the
body is detected and the immune system is able to respond. This assumption leads to the incorpora-
tion of a discrete time delay in the function describing the immune system stimulation by presence of
the tumour cells. For the obtained system the basic mathematical properties of the model, the possible
asymptotic behaviour of the system depending on the delay and the role of the native background im-
munity and the immune stimulation strength are investigated. For the particular form of the stimulus
function the considered model is validated with two sets of the experimental data for particular tumour
cell line and further studied in the context of the model dynamics within the framework of the other
experimental data. It is shown that model can reflect different patterns, including periodic, reported
in the experimental literature. For the estimated parameter values it is shown that an increase of the
background immunity or the stimulation strength of the tumour cells on the immune system enlarge
the stability region for the positive dormant steady state. Moreover, the increase of the background
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immunity might stabilize the unrestricted tumour growth observed for the control experiment.
The paper is organized as follows: in Section 2 the model without delay and summary of the
existence and stability of the non-negative steady states are presented; in Section 3 the model with
discrete delay is described and analysed. Next, in Section 4 model is validated with the experimental
data. The numerical simulations confirming and extending the analytical results are shown in Section
5. Finally, in Section 6 above results are summarised and discussed.
2 Presentation of the base model
In [19] a simple model for tumour-immune system interaction, that takes into account the two most
important variables: the size of specific anti-tumour immunity at time s (X(s)) and the size of tumour
(Y(s)), is studied. To describe the size of the overall specific immunity against the tumour Forys´ et
al., [19], make the following assumptions. First, in the absence of tumour antigens one observes a
constant (with rate w) production of precursor cells that are able to respond to the tumour antigens
and the natural death of the cells, which is expressed by a linear term uX. Thus, as a consequence
of the tumour absence within the body a constant immunity level (so-called background immunity) is
kept. Second, the presence of tumour antigens stimulate an increase of the immunity level. Moreover,
it is assumed that immunity response is proportional to the current size of the immunity X with the
proportionality coefficient (aF), which is assumed to be a bounded function of both immunity size and
tumour antigens or tumour antigens only. It is also assumed that the creation of the antibody-antigen
complexes lead to the death of the immune cells and it is modelled by a bilinear term XY with constant
coefficient b. Clearly, if for particular tumours this process is not observed, then b = 0. Finally, the
destructive influence of immune system on the tumour development is described by the bilinear term
XY with the constant rate c, similarly as it was assumed in [16]. Additionally, it is assumed that the
tumour grows according to the exponential law, as e.g. in [14, 18, 20], with growth rate equal to r.
The system proposed in [19] has the following form
dX
ds
= w − uX + aF(X,Y)X − bXY, (2.1a)
dY
ds
= Y(r − cX), (2.1b)
where the presence of tumour antigens that stimulate the immune system response (F) is defined by
F1(X,Y) =
Yα
kα1 X
α + Yα
, or F2(X,Y) =
Yα
kα2 + Y
α
. (2.2)
Different forms of F1 and F2 reflect different assumptions on tumour–immunity interactions, and both
of them were earlier considered in the literature in the context of the immune system response. For
F = F2 it is assumed that the number of stimulated cells does not depend on the size of the immune
system itself, hence stimulation is signal dependent. Such a form of the stimulus function in the
context of immune response was considered for example in [4, 27–29] and more recently in [19, 21,
25]. In case of F = F1 a number of signal molecules need to be reached before faster production
of immune cells is activated (after which, the size of anti-tumour immunity increases) hence such a
function is often called a ratio-dependent stimulation function and it was considered in the immune
system - tumour interactions context in [3].
Due to the biological interpretation of constants, it is assumed that all parameters are non-negative
and in particular parameters a, c, u, r, w and ki, i = 1, 2 are strictly positive. Moreover, it is assumed
that α, which describes the switching characteristics of the stimulus functions, is greater or equal to
1.
4In order to simplify the model analysis, in the analytical part of the paper, its non-dimensional
form is considered
dx
dt
= d
(
ω − x + ρ f (x, y)x − ψxy), (2.3a)
dy
dt
= y(1 − x), (2.3b)
where ω = cw/(ur) > 0 is the native (background) immunity, i.e. the natural level of immunity in the
absence of antigens, ρ = a/u > 0 is the stimulation strength, ψ = bY0/u ≥ 0 (Y0 = k1r/c or Y0 = k2
depending on the form of F function considered) is the strength of anti-immune activity, d = u/r > 0
and f (x, y) is the stimulus function given by
f1(x, y) =
yα
xα + yα
or f2(x, y) =
yα
1 + yα
, α ≥ 1, (2.4)
time and variables are scaled t = rs and x = cX/r, y = Y/Y0, respectively.
As mentioned before in the well established literature the stimulating effect of the presence of
tumour antigens on the immune system response is usually described by the function f = f2 and often
( [4,21,25,29]) with α = 1 (that is by the Michaelis-Menten function). Hence, that form is considered
in the part of paper devoted to the model fitting to the experimental data and its further validation.
However, function f2 given by (2.4) has several general properties, thus for the theoretical part on the
paper a more general family of stimulus functions, fulfilling conditions:
(A1) the function f is a non-negative Lipschitz continuous on ≥ = [0,+∞);
(A2) f (y) is bounded by one for all y ∈ ≥;
(A3) f (0) = 0, lim
y→+∞ f (y) = 1, f (1) = 1/2;
(A4) f (y) is increasing for all y ∈ ≥;
(A5) f (y) is differentiable for all y ∈ ≥;
(A6) the function f has at most one inflection point.
and if further needed the additional smoothness
(A7) f (y) ∈ C2 for all y ∈ ≥,
is considered.
Clearly, assumption (A1) together with the form of the system (2.3) guarantees existence of non-
negative unique solutions of (2.3) with non-negative initial condition (3.2). Additionally, the global
existence of the solution is a consequence of the assumption (A2).
In [19] the importance of parametersω (background immunity) and µ = ω−1+ρ, (so-called overall
immune capacity) is stressed since both of them strongly influence the existence and the stability of
the steady states. Hence, due to the biological interpretation of the parameter µ in the rest of the paper
its positivity, i.e.,
ω + ρ > 1
is assumed.
Because of the form of Eq. (2.3b) all non-negative steady states are always of the form (ζ, 0) or
(1, ζ), where ζ > 0. Assumption f (0) = 0 (see (A3)) implies that there always exists a semi-trivial
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steady state A = (ω, 0). Clearly, the existence and number of positive steady states depends on the
number of solutions of equation
ρ f (y) = ψy + 1 − ω. (2.5)
Assumption (A6) implies that there exist at most three positive solutions of (2.5). If ψ = 0, then
due to (A3) and (A4) there exist no positive solutions of (2.5) for ω > 1 and there exists exactly one
yR for max{0, 1 − ρ} < ω < 1. If ψ > 0, then the situation is more complicated. If the function f has
no inflection point (the assumption (A3) implies that f is concave), then for 0 < ω < 1 Eq. (2.5) has
zero or two solutions in a generic case. On the other hand, for ω > 1 Eq. (2.5) has exactly one positive
solution. If the function f has one inflection point, Eq. (2.5) has one or three positive solutions for
ω > 1 and zero or two for 0 < ω < 1 (in a generic case).
Arguments analogous to those presented in [19] imply that the stability of the steady states of the
system (2.3) with f fulfilling conditions (A1)-(A6) are the same as for particular forms of f functions
given by (2.4). The results regarding the existence and stability of the steady states of (2.3) are
summarized in Tab. 1 and partially in Fig. 1. Note that, in [19] additionally it is shown that there are
no periodic solutions of the system (2.3).
Table 1: Existence and stability of the steady states of the system (2.3) for f fulfilling conditions
(A1)–(A6) depending on values of parameters α, ω, ψ, ρ. Numbers in the column ips indicate the
number of possible inflection points of the function f .
ψ ω ips Steady states Stability
Semi-trivial steady states
ψ ≥ 0 0 < ω < 1 0, 1 A = (ω, 0) unstable
ω > 1 locally stable
Positive steady states
ψ = 0
0 < ω < 1∗ 0, 1 R = (1, yR), yR > 0 globally stable
ω > 1 none
ψ > 0
0 < ω < 1 0, 1
none
B = (1, yB), C = (1, yC) B locally stable
0 < yB < yC C unstable
ω > 1
0, 1 C = (1, yC), yC > 0 B unstable
1 B = (1, yB), C = (1, yC), D = (1, yD) B unstable
0 < yB < yC < yD C locally stable
D unstable
∗ under assumption ω + ρ > 1
Since in a later section of the paper f is given by the Michaelis-Menten function, the conditions
for the existence of positive steady states of the system (2.3) for α = 1 and f = f2 are directly provided
below (compare with Figure 1).
Proposition 2.1 Let ψ = 0 and f = f2 is given by (2.4), then
(i) for ω > 1 there are no positive steady states of the system (2.3);
(ii) for max{0, 1 − ρ} < ω < 1 there is exactly one positive steady state of the system (2.3) given by
R = (1, yR) =
(
1,
( 1 − ω
ρ + ω − 1
) 1
α
)
.
Proof : Because of the form of Eq. (2.3b) all positive steady states are always of the form (1, ζ),
where ζ > 0. Clearly, the existence and number of positive steady states depends on the number of
solutions of (2.5). For ψ = 0, due to the facts: f (0) = 0, lim
y→+∞ f (y) = 1 and f being increasing, there
exist no positive solutions of (2.5) forω > 1 and there exists exactly one ζ for max{0, 1−ρ} < ω < 1.
6Proposition 2.2 Let ψ > 0, α = 1, f = f2 is given by (2.4) and ∆ = (1 + (1 − ω − ρ)/ψ)2−4(1−ω)/ψ,
then
(i) for ω > 1 there exits a unique positive steady state C = (1, yC) of the system (2.3) with
yC =
1
2
(
ρ + ω − 1
ψ
− 1 + √∆
)
. (2.6)
(ii) for 0 < ω < 1 and ρ >
(√
ψ +
√
1 − ω)2 two positive steady states (1, yB) and (1, yC) of the
system (2.3) exist where
yB =
1
2
(
ρ + ω − 1
ψ
− 1 − √∆
)
and yC is given by (2.6). On the other hand, if 0 < ω < 1 and ρ <
(√
ψ +
√
1 − ω)2, then there
are no positive steady states of the system (2.3).
Proof :
Eq. (2.5) takes form ρy =
(
ψy + 1−ω
)(
1 + y
)
. Dividing both sides by ψ and denoting β = 1−ω
ψ
and
ν = ρ
ψ
one obtains
y2 + (1 − ν + β)y + β = 0. (2.7)
Inequality ω > 1 implies β < 0, hence Eq. (2.7) has one positive solution and the part (i) follows.
For 0 < ω < 1 there is β > 0. If real roots of (2.7) exist, then they have the same sign. Moreover,
they are positive if and only
ν > 1 + β. (2.8)
On the other hand, the existence of real solutions to (2.7) depends on the sign of the determinant
∆ = (1 − ν + β)2 − 4β = ν2 − 2ν(1 + β) + (1 − β)2. It can be easily calculated that ∆ > 0 if and only if
ν <
(
1 − √β)2 or ν > (1 + √β)2. (2.9)
Note, that for β > 0 the first inequality of (2.9) is equivalent to ν < 1+β−2√β, which contradicts (2.8).
On the other hand, the second inequality of (2.9) is equivalent (again for β > 0) to ν > 1 + β + 2
√
β,
which implies (2.8). Thus, the part (ii) follows.
1
1
0
1 stab. 0
ω
ρ ψ = 0, α = 1
1
ψ
0
1 unstab.
1 stab.
1 unstab.
ω
ρ
ψ > 0, α = 1
Figure 1: The ω−ρ space divided into regions where different numbers of steady states for α = 1 and
ψ = 0 or ψ > 0 are observed. Numbers and text in the regions indicate the number of positive steady
states of the system (2.3) for f = f2 and theirs stability for τ = 0; abbreviations stab. and unstab.
stand for stable and unstable, respectively.
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3 Model with discrete time delay
The immune system requires some time before the presence presence of the tumour (or rather, the
tumour’s antigens) in the organism is detected and the immune system is able to respond. From the
mathematical point of view, to reflect such phenomena, one can include time lags into the system,
e.g. by introducing a discrete delay into the stimulus function. Although the model itself differs
from the one considered in [21], the idea presented there of introducing one discrete time delay only
in the function describing the stimulating effect of the tumour on immune cells proliferation in the
system variable representing the tumour cells compartment is followed here. That assumption reflects
situation when the immune system response due to the presence of the tumour cells depends on the
amount of the immune system cells at a given time t and on the amount of tumour cells at time t − τ,
where τ > 0 is the time needed for the immune system to develop a suitable response after antigens
recognition. Following that approach time lag is introduced in a classical way, as it is done in the
logistic model by Hutchinson [30] or in the Gompertz model [31, 32], where delay is introduced to
the function representing the per capita growth rate. The same assumption of the form of time delay
in the model of the immune system-tumour interactions has been recently made e.g. in [24]. Clearly,
in the literature [15, 17, 18] discrete delay in the variable representing the size of the immune system
was also considered. However, this idea is not followed since the priority is given to the immune
system’s time reaction. It is also assumed that the immune system does not require time to know the
size of itself.
The non-dimensional system with one discrete delay has the following form
dx(t)
dt
= d
(
ω − x(t) + ρ f (y(t − τ))x(t) − ψx(t)y(t)), (3.1a)
dy(t)
dt
= y(t)(1 − x(t)), (3.1b)
where function f fulfils conditions (A1)-(A6) (and (A7) if needed).
To close system (3.1) one needs to define the initial condition
x(t) = ϕ1(t), y(t) = ϕ2(t), for t ∈ [−τ, 0], ϕ1(t), ϕ2(t) ∈ C, (3.2)
where C = C ([−τ, 0],R≥) denotes the set of continuous functions defined on the interval [−τ, 0]
with non-negative values. Clearly, since in system (3.1) only y variable has delayed argument model
dynamics will depend on ϕ1(0) and ϕ2(t).
Theorem 3.1 Let f fulfils assumptions (A1)-(A2), then there exists a global, unique and non-negative
solution of system (3.1)-(3.2).
Proof : For t ∈ [0, τ] y(t − τ) = ϕ2(t − τ) ≥ 0 is well defined thus for ϕ1(t), ϕ2(t) ∈ C, under assump-
tion (A1), there exists an interval [0, t∗) ⊂ [0, τ] where the solution (x(t), y(t)) of the system (3.1)
exists and is unique, for details see [33].
Re-writing Eq. (3.1b) in the integral form (y(t) = ϕ2(0) exp
∫ t
0
(1 − x(s))ds) one obtains non-
negativity of y(t) whenever it exists. Now, assume that at point t1 ∈ (0, t∗) x(t) starts to be nega-
tive, i.e. x(t) > 0 for 0 < t < t1, x(t1) = 0 and x˙(t1) ≤ 0. Clearly, for considered f (y) inequality
x˙(t1) = d
(
ω− x(t1) + ρ f (y(t1 − τ))x(t1)−ψx(t1)y(t1)) = dω > 0, holds. That contradicts the hypothesis
that solution x(t) starts to be negative for t = t1.
On the other hand, the non-negativity of x(t) and y(t) imply y(t) ≤ ϕ2(0)et∗ . Moreover, stimulus
function f (y) fulfils assumptions (A1)-(A2). Hence, x˙ ≤ d(ω + ρx) and x(t) ≤ edρt∗
(
ϕ1(0) + ωρ
)
− ω
ρ
.
Thus, both variables and theirs derivatives are bounded, so the solution can be extend through the
point t∗. Following the method of steps (see e.g. [33]) and repeating presented arguments for each
interval [nτ, (n + 1)τ], n ∈ N one completes the proof.
83.1 Stability of the steady states
Clearly, the steady states of the system with delay (3.1) are the same as for the system without de-
lay (2.3). However, the system’s stability, already strongly depending on the values of parameters φ
and ω without delay, now can also depend on the value of parameter τ.
Theorem 3.2 Let f fulfils conditions (A1)–(A5). The semi-trivial steady state A = (ω, 0) of sys-
tem (3.1)-(3.2) is a locally stable node for ω > 1 and a saddle for ω < 1 independently of the value
of parameter τ ≥ 0.
Proof : For τ = 0 steady state A is a locally stable node (for ω > 1) or a saddle (for 0 < ω < 1) and
it always exists, for details see [19]. Consider τ > 0. Linearising system (3.1) around steady state A
one obtains system without delay which is the same as the linearisation of the system (2.3) without
delay. Hence, parameter τ has no influence on the local stability of semi-trivial steady state A.
As pointed earlier, for all positive steady states the first coordinate equals to 1, thus (1, ζ), ζ > 0
denotes the positive steady state of the system (3.1). Moreover, to simplify the notation define
γ f := ρ f ′(ζ) = ρ
αζα−1
(1 + ζα)2
> 0, (3.3)
which is positive due to the assumption (A4).
Theorem 3.3 Let f fulfils conditions (A1)–(A7), ψ ≥ 0 and γ f > 0 is given by (3.3).
1. If ψ − γ f > 0, then the steady state (1, ζ) of system (3.1) is unstable for all τ ≥ 0.
2. If ψ−γ f < 0, then the steady state (1, ζ) of system (3.1) is locally asymptotically stable for τ = 0
and there exists a critical value τζcr such that (1, ζ) is locally asymptotically stable for τ < τ
ζ
cr
and is unstable for τ > τζcr. Moreover, for τ = τ
ζ
cr, the Hopf bifurcation occurs and periodic
solutions arise with period equal to 2pi/
√
ηζ , where
ηζ =
−(2dζψ + (dω)2) + √(dω)4 + 4d3ζψω2 + 4(dζγ f )2
2
, τζcr =
1√
ηζ
arccos
(
ηζ + dζψ
dζγ f
)
.
(3.4)
Proof : Linearising system (3.1) around steady state (1, ζ) one obtains
dx(t)
dt
= d(−1 + ρ f (ζ) − ψ)x(t) − dψy(t) + ργ f y(t − τ), dy(t)dt = −ζx(t).
Note that for steady state (1, ζ) equality 1 − ρ f (ζ) + ψζ = ω, holds. Thus, the characteristic function
for each positive steady state (1, ζ) has the following form
W(λ) = λ2 + dωλ − dψζ + dζγ f e−λτ . (3.5)
Clearly, for τ = 0 Eq. (3.5) reads W(λ) = λ2 + dωλ − dζ(ψ − γ f ) and for ψ − γ f > 0 it has two real
solutions of opposite signs. Thus, in such a case steady state (1, ζ) is a saddle. On the other hand, for
τ = 0 and ψ− γ f < 0 both roots are real and negative or complex with negative real parts, hence (1, ζ)
is locally asymptotically stable. From the continuous dependence, one knows that for sufficiency
small delays this result holds, however, the stability of the steady state(s) might change for a larger
values of delay, see e.g. [33]. Such a situation is only possible if there exists a critical value τ = τζcr
and a pair of purely imaginary roots of (3.5) such that roots cross the imaginary axis (in the proper
direction) when τ exceeds τζcr.
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Let ±iθ be a pair of pure imaginary roots of (3.5). Hence, W(iθ) = −θ2+idωθ−dζψ+dζγ f ( cos θτ−
i sin θτ
)
= 0, and
cos θτ =
θ2 + dψζ
dζγ f
> 0, sin θτ =
dωθ
dζγ f
> 0. (3.6)
A solution of system (3.6) exists if condition dζ(ψ − γ f ) ≤ −θ2 is fulfilled. Hence, for ψ − γ f > 0
the characteristic quasi-polynomial (3.5) of the system (3.1) has no purely imaginary roots and hence
the real parts of eigenvalues can not change sign for any value of τ ≥ 0. That completes the proof of
part 1.
Consider ψ − γ f < 0. Squaring and adding Eqs. (3.6) one has
F˜(θ) := θ4 + d
(
2ψζ + dω2
)
θ2 + d2ζ2
(
ψ2 − γ2f
)
= 0. (3.7)
Next, substituting η = θ2 one gets η2 + η((dω)2 + 2dζψ) + (dζ)2(ψ2 − γ2f ) = 0 with roots given by
η
ζ
1,2 =
−(2dζψ + (dω)2) ±
√
(2dζψ + (dω)2)2 − 4(dζ)2(ψ2 − γ2f )
2
. (3.8)
Clearly, roots (3.8) are always real since the expression (2dψζ + (dω)2)2 − 4(dζ)2(ψ2 − γ2f ) is strictly
positive for ψ − γ f < 0. Moreover, for ψ − γ f < 0 roots have opposite signs. Denote the positive root
by ηζ1 > 0, then there exists θ¯
ζ =
√
η
ζ
1 such that 0 < (θ¯
ζ)2 + 2dζψ < dζγ f , and moreover W(iθ¯ζ) = 0
for an infinite sequence of critical values of τ given by
τ
ζ
cr,k =
1
θ¯ζ
arccos

(
θ¯ζ
)2
+ 2dζψ
dζγ f
 + 2kpi
 , k ∈ N0. (3.9)
Denote by τζcr the first positive delay fulfilling condition (3.9). To complete the proof one needs to
show that the real part of eigenvalues of roots cross the imaginary axis at τ = τζcr with positive speed,
i.e. ∂
∂τ
Reλ(τ)|τ=τζcr > 0 and that the re-stabilization of the positive steady state is not possible for larger
values of τ. Here, using the theorem proved by Cooke and Van den Driessche in [34], one can show
that all the roots of the characteristic quasi-polynomial (3.5) cross the imaginary axis from the left to
the right-hand side of the complex plane. The Cooke and Van den Driessche theorem indicates that
∂
∂τ
Reλ(τ)|τ=τζcr,k =
dF˜(θ)
dθ |η=η¯cr , hence it is enough to calculate dF˜(θ)dθ = 4θ3 + 2dθ(2ψζ + dω2) > 0 for θ > 0.
Thus, in the case when the steady state is locally asymptotically stable for τ = 0, for τ = τζcr new
periodic orbits arise due to the Hopf bifurcation with period equal to 2pi/θ¯ζ . Moreover, destabilized
steady state (1, ζ) remains unstable for all τ > τζcr. That completes the proof.
4 Experimental data, estimation of parameters and model vali-
dation
The model parameters are obtained by fitting the solutions of the non-scaled version of model (3.1)
to the experimental data provided in [35] for mice affected by B-cell lymphoma in the spleen (BCL1).
It is assumed that F is given by the Michaelis-Menten function (F = F2 defined by (2.2) with α = 1)
since it is the most common form of the stimulation function considered in that context in the litera-
ture, see e.g. [4, 21, 25, 29]. Estimation of the ranges for each parameter is based on the experimental
literature as well as on the assumptions made by other scientists who in particular modelled the BCL1
and DLBCL (diffuse large B-cell lymphoma) progression or modelled the tumour-immune system
interactions in general [4, 13, 18, 25, 29, 36].
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4.1 Experimental data
The solutions to non-scaled version of model (3.1) are fitted to the experimental data for BCL1
from [35], where the modelled experiment was performed on two sets of animals: the control group
(BALB/c mice) and chimeric. Chimeric animals were obtained from BALB/c mice by having, by
lethal irradiation, their bone marrow destroyed and then having bone marrow transferred from other
mice to rebuild the immune system. In normal BALB/c mice, one observes that 5×105 injected BCL1
cells into the spleens grew rapidly, reaching a plateau after 40 days and causing mice death by 90
days. In contrast, identically injected groups of chimeric animals demonstrated a different growth
pattern: the initial rate of growth was similar to the control group, but then it slowed down with tu-
mours reaching their maximum sizes (10 times smaller than in control mice) and a commensurate
decrease in the number of cells was observed after day 40, see Figure 2.
4.2 Parameter ranges
Tumour growth rate (r). Tumour volume duplication time strongly depends on the tumour type.
For some tumours it can be 20 days, while for others, e.g. colon cancer, it can be years. On the
other hand, the tumour doubling time for malignant lymphoma is reported to be around 29 days, [37].
In [36], for DLBCL, it was assumed that the tumour doubling time is between 1.4 and 70 days which
corresponds to a tumour growth rate between 0.0099 and 0.4951 day−1 (approximately 0.01 and 0.5
day−1). That assumption is followed since the interval [0.01,0.5] includes the range 0.05-0.5 proposed
in [25]. Clearly, the tumour growth rate estimated by Kuznetsov et al. in [4] (0.18 day−1) also lies in
that interval.
Natural lymphocyte death rate (u). The mean lifetime of T lymphocytes from the spleen and
the blood was estimated to be approximately 30 days or more, [38]. Thus, the degradation rate, which
is 1/(mean life time), is assumed to be in the range 1.25×10−2−5×10−2 day−1, which corresponds to
20− 80 days mean life time. The values of the death rate 0.03125 and 0.0412 day−1 estimated in [25]
and [4], respectively, also lie in the assumed range.
Immune response function (F, α, k2, a). It is assumed that the immune system response term
has the same form as those considered e.g. in [4, 13, 21, 25, 29] or [36], that is F = Yα/(kα2 + Y
α)
with α = 1. In [4] the value of the steepens of the immune response function (k2) was estimated to be
2.019 × 107 cells, while in [25] the value 1.5109 × 107 cells. In this study the range of 107 − 2 × 108
cells for k2 is chosen. To determine the range of the maximal immune system response rate (a) [25]
is followed and range 0-2.5 day−1, which contains the value 0.1245 day−1 estimated in [4], is taken.
Tumour independent production rate of effector cells (w). Following [25] the range for the
constant influx of effector cells (w) from the immune system in the absence of tumour is chosen to
be 3.2 × 103 − 3.2 × 104 cells day−1. The value 1.3 × 104 cells day−1 estimated by [4] belongs to the
considered range.
Tumour-induced inactivation rate of effector cells (b). In [25] the range for the fraction of
immune cells inactivated due to the interactions with tumour cells (w) was assumed to be 10−12 − 5 ×
10−7 cells−1 day−1. The value 3.422 × 10−10 cells−1 day−1 estimated in [4] belongs to the assumed
range.
Effector induced elimination rate of tumour cells (c). In [18] the range for the fraction of cancer
cells killed per effector cell was assumed to be 10−9 − 10−7 cells−1day−1. However, in [4] the value of
that parameter was estimated to be equal to 1.101 × 10−7 cells−1day−1. Hence, the range is extended
and it is assumed to be c ∈ [10−9, 3 × 10−7].
Time delay in the immune system activation (τ¯). In this study it is assumed that time delay in
immune system response is in range from 1h till 5 days, i.e. 0.0416-5 days.
All ranges of the model parameters together with corresponding references are given in Table 2.
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Table 2: Parameter ranges with referenced used for the fitting procedure to the experimental data
from [35].
Par. Biological interpretation Unit Range Reference
w tumour independent production
rate of effector cells
cells day−1 3.2 × 103 − 3.2 × 104 [25], [4]
u natural lymphocyte death rate day−1 1.25 × 10−2 − 5 × 10−2 [38] [25], [4].
a maximal immune response rate day−1 0-2.5 [25], [4]
b fraction of immune cells inacti-
vated in interactions with tumour
cells
cells−1 day−1 10−12 − 5 × 10−7 [25], [4]
r tumour growth rate day−1 0.01 − 0.5 [36], [25], [4],
[37]
c fraction of cancer cells killed per
effector cell
cell−1 day−1 10−9 − 3 × 10−7 [18], [4]
τ¯ time delay day 0.0416 − 5 ass.
k2 steepens of immune response cells 107 − 2 × 108 [25], [4]
α detrmines type of immune re-
sponse
– 1 [4], [13], [29],
[21], [25], [36]
4.3 Estimation of model parameters
Clearly, if there are no tumour cells in the system (Y = 0), then immune-activity stays at the constant
level calculated directly from (2.1a). Hence, the initial condition for the variable X is a constant
equal to w/u. On the other hand, to determine the level of the tumour cells at the beginning of the
experiment (at s = 0) one can directly use the data from [35] taking Φ2(0) = 5 × 105 cells. Thus, the
initial condition for non-scaled version of (3.1) reads
Φ1(s) =
w
u
for s ∈ [−τ¯, 0], and Φ2(s) =
0 for s ∈ [−τ¯, 0),5 × 105 for s = 0, (4.1)
and due to the dependencies on the parameters w, u and τ¯ = τ/r the initial condition is estimated
within the fitting procedure.
The fitting procedure is performed in the commercial MATLABr computational environment
using the PSO function. PSO finds a minimum of a function of several variables using the particle
swarm optimization algorithm based on the stochastic optimization technique that was inspired by
the social behaviour of bird flocking or fish schooling. The algorithm was originally introduced in
1995 by Kennedy and Eberhart, [39], and later extended by Shi and Eberhart, [40]. Nowadays it has
a number of extensions, however the main idea is the same a swarm of particles moves around in
the search space and the movements of the individual particles are influenced by the improvements
discovered by the others in the swarm. In [41] Clerc and Kennedy introduced a constriction factor
in PSO, which was later shown to be superior to the inertia factors. That version of algorithm is
used here. Solutions of delay differential equations (DDEs) are computed using dde23 function with
tolerance RelTol =1e-7, and AbsTol=1e-11.
In the presented study the objective function is the standard one based on the calculation of mean
square error (MSE):
MSE =
1
m
m∑
i=1
err2i , erri =
xdatai − xsymi
xdatai
,
where m is the number of experimental measurements, xdatai are the measured values and x
sym
i are the
values of the solution of DDEs for respective time points.
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Table 3: Fitted non-scaled model parameters, steady states and theirs stability for τ¯ = 0 for non-scaled
system (3.1). Parameter α=1.
control chimeric
parameters
w 3.0337 × 104
u 0.0196
a 0.1452 0.2835
k2 1.3604 × 108 1.8720 × 108
b 2.1010 × 10−10 6.6828 × 10−10
r 0.4695
c 1.7608 × 10−7 2.0761 × 10−7
τ¯ 3.1869 0.0581
steady states and theirs stability for τ¯ = 0
semi trivial unstable (1.5472 × 106, 0) (1.5472 × 106, 0)
positive stable (2.6666 × 106, 1.0548 × 107) (2.2616 × 106, 7.8919 × 106)
positive unstable (2.6666 × 106, 5.0530 × 108) (2.2616 × 106, 2.1986 × 108)
Table 4: Fitted model parameters for system (3.1), parameter α=1.
d ω ρ ψ τ
control
0.0418
0.5802 7.4046 1.4576 1.4964
chimeric 0.6841 14.4583 6.3802 0.0273
First, the solutions of the non-scaled version of system (3.1) are fitted to the data from the chimera
experiment for BCL1 tumour cell population in the spleen of the BALB/c mice over 110 days (de-
scribed in [35]) with the initial condition given by (4.1) that depends on w, u and τ¯ parameter values.
The result of the fitting procedure is presented in Figure 2 (left) showing a good agreement with the
experimental data (with MSE at the level of 3.57%) and thus positively validates the proposed model.
Next, the parameters w, u and r are fixed (as for chimera experiment) and the rest of the parameters
are fitted to the 90 day control mice experiment to further validate the model. This time a very good
agreement with the experimental data with MSE at the level of 0.14% is obtained, see Figure 2 (right).
The corresponding values of the estimated parameters for both experiments are given in Table 3.
5 Results
Comparing the sets of parameters (see Table 3) for both experiments estimated via the fitting proce-
dures one immediately sees that for the chimeric set of parameters parameter a is two times larger
Table 5: Summary of the bifurcation phenomena for scaled parameters given in Table 4 and τ treated
as a bifurcation parameter, α = 1.
Param. type steady state stability τ = 0 τcr period bif. type
control
(0.5802, 0) unstable unstable for τ ≥ 0
(1, 0.0775) stable 1.1776 50.1363 supercritical
(1, 3.7145) unstable unstable for τ ≥ 0
chimera
(0.6841, 0) unstable unstable for τ ≥ 0
(1, 0.0422) stable 1.2227 57.3715 supercritical
(1, 1.1745) unstable unstable for τ ≥ 0
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Figure 2: (Left) Result of the fitting procedure of the trajectories of the non-scaled version of sys-
tem (3.1) to the experimental data for BCL1 tumour cell population in the spleen of the chimeric mice
over 110 days experiment described in [35]. MSE=0.0357. (Right) Result of the fitting procedure of
the trajectories of the non-scaled version of system (3.1) to the experimental data for BCL1 tumour
cell population in the spleen of the BALB/c mice over 90 days control experiment described in [35].
MSE=0.0014. In both panels solutions of the non-scaled version of system (3.1) are computed with
RelTol=1e-7 and AbsTol=1e-11. All used parameter values, for both panels, are given in Table 3.
Bars indicate the measurement errors as reported in [35].
than for the control set. Thus, together with slightly larger k2 (for the chimeric experiment) implies
a stronger stimulation of the immune system due to the presence of the tumour cells. Additionally,
the time lag of that response is much shorter, approx. 1.4 h, for the chimeric set of parameters than
for the control, approx. 76.5 h, indicating a more effective immune system reaction in the presence
of the tumour cells for the chimeric mice. For both the chimeric and control sets, the estimated value
of the tumour cells killed per effector cells (c) is very similar. Despite the large range for parameter b
(10−12 − 5 × 10−7, see Table 2) and that no further assumptions on the range of b to differentiate the
chimeric and control experiments are made, the fitted values obtain the same order of magnitude.
The simulations presented in Figure 3 again validate positively the model and confirm results
from [35] showing that for larger than control initial injection of populations of the tumour BCL1
cells into the spleens of the chimeric mice leads to the same growth pattern. Experiments performed
in [35] indicate that even if one injects 5× 107 cells after around 110 days, due to the immune system
response, the number of tumour cells is reduced to the almost the same amount as for 5× 105 initially
injected cells. To reproduce that phenomena all used parameter values were fixed, as given in Table 4
(column chimeric) and only a part of the initial condition that is Φ2(0) was changed, see Figure 3.From
the mathematical point of view such behaviour shows that the stable steady state, that can be identified
as a dormant tumour state, has large enough basin of attraction.
For the sets of estimated parameters that have been scaled and are given in Table 4 the system (3.1)
has one semi-trivial steady state which is equal to (0.5802, 0) and (0.6841, 0) for the control and
chimeric parameter sets, respectively. For both sets of parameters ω < 1, thus both semi-trivial steady
states are unstable. Moreover, according to Theorem 3.2 they stay unstable independently of the value
of time delay.
Additionally, for both sets of parameters, assumptions of Proposition 2.2 are fulfilled and thus,
for both cases the system (3.1) has two positive steady states: Bc = (1, 0.0775) and Cc = (1, 3.7145)
for control; Bchim = (1, 0.0422) and Cchim = (1, 1.1745) for chimera. Interesting is that the values of
the positive steady states Bchim and Bc are similar. For τ = 0 one can easily check that the steady
states Bc and Bchim are locally asymptotically stable, while the steady states Cc and Cchim are unstable,
see Table 5. Considering τ as a bifurcation parameter and using results of Theorem 3.3 one obtains
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Figure 3: Trajectories of the non-scaled version of tumour-immune system (3.1) for initial condition
as defined in (4.1) with different values of Φ2(0): 5 × 105 (dash green line), 5 × 106 (dash-dot blue
line) and 5 × 107 (solid red line). All used parameter values are given in Table 3 (column chimeric),
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Figure 4: (Left) Critical values of the bifurcation parameter as the functions of ω (left) and as the
functions of ρ (right) for both chimeric (red dash line) and control (blue solid line) sets of parameters.
All used parameter values (except ω, ρ and τ) are given in Table 4. The stability regions lie below the
solid blue and the dashed red lines. The horizontal grey dash-dot line in the left panel indicates the
value of delay estimated via the fitting procedure for the control experiment τ = 1.4964.
that independently of the value of time delay the steady states Cc and Cchim remain unstable. The
situation differs for steady states Bc and Bchim, whose stability changes for sufficiently large values
of parameter τ. Moreover, Theorem 3.3 indicates that there can be only a single stability switch for
each Bc and Bchim steady states for time delay treated as a bifurcation parameter. For the considered
sets of parameters the critical values of the bifurcation parameter are 1, 1776 and 1.2227 for control
and chimeric parameter sets, respectively. Theorem 3.3 and the results of the numerical analysis
indicate that for sufficiently large time delay, the periodic behaviour of the solutions of system (3.1)
should be observed if the initial condition is properly chosen.Clearly, for the estimated chimeric set
of parameters the delay value dose not exceed the critical value, thus for that set of parameters the
steady state Bchim is locally asymptotically stable. For the control set of parameters, Bc is unstable
since for τ = 1.1776 the Hopf bifurcation takes place.
The functional dependences of the critical values of the bifurcation parameter (τcr) for the steady
states Bc and Bchim on the model parameters ω and ρ are presented in Figure 4, where all parameters
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are fixed (as in Table 4) except ω, ρ and τ. Figure 4 left indicates that the critical values of time
delays, for both chimeric and control sets of parameters, are the increasing functions background
immunity. Thus, the increase of the native immunity increases the stability region of the steady states
Bc and Bchim. Proposition 2.2 indicates that for 0 < ω < 1 (that is the case of the estimated values of
parameters) and ρ→ (√ψ + √1 − ω)2 (that is ρ→ 9.5355 and ρ→ 3.4419, for chimeric and control
sets of parameters, respectively) the positive steady states merge, thus the critical values τcr can only
be computed for sufficiently large values of ρ. Additionally, there are no upper limits for ρ. Similarly
as in the previous case, τcr for both sets of parameters are increasing functions of ρ. However, this
time they are concave functions. Thus, increasing the stimulation strength enlarges the stability region
of the steady states Bc and Bchim, however in a different manner.
In the general case a large number of model parameters makes the analytical study of the nature
of the Hopf bifurcations, i.e. of the stability of the arising periodic solutions, hard to perform. Thus,
for the estimated model parameters the BIFTOOL package (a Matlab package for numerical bifurca-
tion analysis for DDEs developed by Engelborghs et al.) is used, for details and the documentation
see [42], [43] or visit http://twr.cs.kuleuven.be/research/software/delay/ddebiftool.shtml. In Figure 5
the amplitudes of the periodic solutions as a function of the bifurcation parameter τ for the control
and chimeric sets of parameters (see Table 4) for model (3.1) are presented. Clearly, from the figure
one reads that periodic solutions are born for critical values of τ given in the Table 5 and exist for τ
greater than the critical values of the bifurcation parameter, indicating that the Hopf bifurcations are
supercritical. In both cases, the amplitudes are comparable, having the same order of magnitude. This
result holds for the non-scaled model as well since the parameter r is held constant across both cases,
whilst the fitted value of c has the same order of magnitude between cases.
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Figure 5: Amplitudes of the periodic solutions arising due to the Hopf Bifurcation as a function of
the bifurcation parameter τ for chimeric (left) and control (right) sets of parameters given in Table 4
for model (3.1). In green the predicted values are marked, while in blue the corrected ones.
In Figure 6 (top) the period of periodic solutions arising from the Hopf bifurcations as a function
of τ for control and chimeric sets of parameters are presented. The directly calculated (Theorem 3.3)
values of the periods for critical values of bifurcation parameter are 50.1363 and 57.3715 for control
and chimeric sets of parameters, respectively, see Table 5. Calculating the same for the non-scaled
model gives periods of approx. 107 and 122 days for the control and chimeric sets of parameters,
respectively. These pattern agrees with 3-4 months oscillations observed for the clinical data for
certain kinds of human leukemias and also agrees with oscillatory growth of human and rat tumour
cell lines reported in [44–46] or in [47] for non-Hodgkin’s lymphoma.
Interesting is that such recurrent patterns of tumour remission and re-growth have also been clin-
ically observed for immunized BALB/c mice, where mice where initially immunized with BCL1-
Idiotype before the injection of 106 BCL1 tumour cells and without any further immunization, [35].
For such experiment the level of Anti-Id in serum and spleen sizes where followed for a period of 115
days showing that in several mice the spontanous regression followed by splenomegaly was observed,
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Figure 6: Top: Periods of periodic solutions arising from the Hopf bifurcations as a function of
bifurcation parameter τ for chimeric set of parameters (left) and control set of parameters (right) for
model (3.1). Middle and bottom: Floquet multipliers plotted on the complex plain for the periodic
solutions near the bifurcation points for chimeric (left) and control (right) sets of parameters for
model (3.1). In the bottom row the zoom of the results form the middle row is presented. For all
simulations model parameters are given in Table 4.
compare Figure 5 in [35]. Moreover, Figure 6 (top) indicates that the periods of the periodic solutions
increase with the increase of the bifurcation parameter thus, for larger time lags in the reaction of
the immune system to the presence of antigens, larger periods of oscillation of the tumour mass and
immunity are observed.
In Figure 6 (middle and bottom) the Floquet multipliers plotted on the complex plain for both
sets of estimated parameters are presented. Clearly, the multiplier (0, 1) is the trivial one that always
exists for the autonomous systems, while the ones inside the circle has modulus smaller than 1. Since
periodic solutions are stable if all, except (0,1), multipliers have modulus smaller than one, one con-
cludes that for the parameter values given in Table 4 the arising periodic solutions are stable. This
implies that the supercritical Hopf bifurcations for both sets of parameters are observed, confirming
our previous results presented in Figure 5. From the biological or medical point of view supercritical
Hopf bifurcation is considered as a safe bifurcation (of course assuming that the amplitude of periodic
solutions can not be too large), since although the steady state becomes unstable for larger values of
the bifurcation parameter the new born periodic solutions are stable. In such situations a local stable
limit cycle around the dormant tumour steady state occurs and again some kind of boundedness of tu-
mour growth is observed. Such oscillations around the steady state corresponds to situation where the
tumour grows and shrinks with no application of additional treatment, see the experimental tumour
volume data from [44, 45] or [46].
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6 Discussion
In this paper the interaction between tumour and immune system by a system of non-linear differential
equations with discrete delay, representing time lag in the reaction of immune system to recognition
of the antigens, is described. The mathematical properties of proposed model such as: existence,
uniqueness and non-negativity of solutions are studied. The presented study focusses on the on the
stability of the steady states depending on the value of the bifurcation parameter, which is the time
delay. The direct conditions for the stability of the steady states are derived in this paper. In the
general case, it is shown that depending on assumptions on the model parameters the stability of the
system changes due to Hopf bifurcation for sufficiently large delay. Moreover, only one such stability
switch is possible. Additionally, it is shown that the unstable (for τ = 0) steady states remain unstable
independently of the values of delay.
Next, the proposed model is calibrated with two sets of the experimental data for BCL1 tumour
cells injected to the mice spleens, [35], with MSEs at the level of 3.57% and 0.14%. For the estimated
values of parameters, the proposed model is further validated with other experiments for different
initial numbers of injected cells. For both sets of estimated values of the parameters the considered
model has two positive steady states and one unstable semi-trivial steady state. For the chimeric set
of parameters there are stable and unstable positive steady states, which indicate a local stabilization
(dormancy) of tumour growth at finite size if the initial size of tumour is sufficiently small (as in
case of considered experimental setup) or infinite tumour growth otherwise. For the estimated control
set of parameters both positive steady states are unstable, however the periodic orbits exist. That
means that depending on the initial conditions the unrestricted tumour growth (as for the control set
of parameters) or periodic oscillations of tumour size are observed.
The second coordinates of the positive stable steady state for the chimeric set of the parameters
and positive steady state (that is stable for sufficiently small delay) for the control set of parameters
are similar. Hence, by decreasing the time response of the immune system to the presence of the
tumour cells one might stabilize the uncontrolled tumour growth in case of the control experiment.
Additionally, for both estimated sets of parameters (except time delay treated as a bifurcation
parameter) the presented analytical study is extended by investigating the stability of the new born
periodic orbits and thus the type of existing Hopf bifurcations. It should be pointed out that the
oscillatory behaviour of the multicellular tumour volume was experimentally observed, even with-
out administration of any treatment, as reported for the in vitro experiments for human and rat cell
lines reported in [45] and [44]. Such oscillations are explained e.g. as the effect of non-linear feed-
back between proliferation at the multicellular tumours surface and invasion of the surrounding by
tumour cells leaving the spheroid surface however other scenarios are also discussed. The oscillating
growth phenomenon is also observed for the in vivo studies and take place for e.g. the mice initially
immunized with BCL1-Idiotype before the injection of 106 BCL1 tumour cells or in non-Hodgkin’s
lymphoma [47].
Although the model is rather simple, its dynamics might be complex and reflect a number of bio-
medical phenomena such as: therapy failure considered as a modification of model parameters, i.e.
an unrestricted growth of the tumour; stabilisation (at least temporary) of tumour growth at a finite
size – dormancy; and desirable regression of the tumour. If the initial size of the tumour (or rather
amount of antigens) is strictly greater than zero, then according to the values of the model parameters
seven different scenarios are possible: (i) asymptotic unrestricted growth of the tumour independently
of the initial tumour size; (ii) stabilisation of the tumour growth independently of initial tumour size
(existence of globally stable equilibrium); (iii) global eradication of the tumour by the immune system
independently of the initial tumour size; (iv) local stabilisation of tumour growth at a certain finite
size (if the initial tumour size is sufficiently small one observes stabilisation of the tumour growth
at a finite size, otherwise unrestricted growth); (v) local eradication of the tumour by the immune
system (for sufficiently small initial size tumour will be eradicated by the immune system, otherwise
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it will grow unrestrictedly); (vi) bi-stability with eradication for sufficiently small initial tumour,
stabilisation on a finite size of tumour of medium initial size and unrestricted growth for large initial
tumour when two locally stable steady states co-exist; and finally (vii) recurrent patterns of tumour
remission and re-growth. The first six of these features can be observed for the model without time
delay, while the last one it is not possible since the ODE model has no periodic solutions. Hence,
the DDE model can reflect the oscillatory phenomenon observed for a range of tumour types and in
particular in lymphoma.
The main goal of the any-anticancer therapies is to treat disease or at least control its progression.
Form the mathematical point of view this means that one wishes to ensure that the trajectories of
the system are in the region of attraction of the proper steady states. To do that at the level of the
considered model one can try to increase or decrease some of the parameters. In the context of
immunotherapy several attempts to increase the immune system efficiency or the creation of anti-
tumour immunity were already proposed in many different ways [1, 48, 49]. One can consider the
increase of the native immunity e.g. by proper incubation of a patient’s natural killer lymphocytes to
enhance their activity and later by their infusion of them into the patient body. In the mathematical
language that would mean the increase of the ω parameter which is crucial for reaching the global
or local eradication of the tumour or the bi-stability phenomenon (depending on the values of the
other system parameters). Recall that ω = wc/(ur). Clearly, since the natural lymphocyte death rate
(u) and the tumour growth rate (r) are rather out of reach of immunotherapy one should thus focus
on increasing w and c parameters, that is stimulation of the production strength and the effectiveness
of effector cells. The increase of the effective cells can be reached by the infusions of the cells
grown ex vivo, while the increase of the killing effectiveness of the cells can be obtained as the
result of the infusion of properly chosen cytokines, [1]. On the other hand, parameter r can be for
example decreased by different types of chemotherapies. Another parameter that has an essential role
in determining the range of the controlled tumour growth is the stimulation strength ρ = a/u. If
the tumour antigens are not presented to the lymphocytes, one can increase a by method of artificial
loading of the of antigen-presenting calls with tumour antigen. The effectiveness of such an approach
will be dictated by the values of the background immunity and strength of the anti-immune activity.
In this paper, it is shown that for the model with discrete delay and estimated parameters an increase
of the background immunity (ω), as well as the stimulation strength (ρ) of the tumour cells on the
immune system, causes the increase of the critical delay value for which the Hopf bifurcation is
observed, enlarging the stability region for the positive dormant steady state, see Figure 4. Hence, by
increasing the background immunity (range is reachable) one might stabilize the unrestricted tumour
growth observed for the control experiment.
On the other hand, if one wishes to model the effectiveness of a given therapy or try to increase a
given therapeutic effect one should rather directly include these elements in the system, e.g. by adding
new terms and considering the optimization problem. That of course would force the additional
calibration of the extended model with additional sets of experimental data required. Researchers who
are interested in collaborating with experimentalists or clinicians who have access to patients or in
vivo animal trial data should feel encouraged to follow this idea. Recently the very promising concept
of an anti-tumour vaccines has arisen, [1, 48]. However, due to the discrete nature of the vaccination
program, the presented model would need to be adapted to include an impulse-response framework.
In that context, the presented calibrated model can be a base for the future study of the effectiveness of
a different types of therapies, including the chemotherapy or combined chemo-immunotherapy. One
should feel free to modify the proposed model by fitting it to appearing needs. For example one can
consider instead of the exponential tumour growth rather the Gompertz one, which takes into account
the finite environmental capacity for tumour cells. That might cause an essential qualitative difference
between models. However, it is still an open question. On the other hand, to fit even better proposed
model with the experimental data one could instead of the discrete delay consider the distributed one
that often better reflects the real measurements.
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